SMi Reports: Renowned industry experts to present on Disruptive Technologies in Pharma conference taking place in January 2020.
Industry case studies will reveal personal experiences and strategies to approaching digitalisation, providing a benchmark for practice and improving understanding of forecasts until 2020.
Other featured speakers include:
Joseph Dalton, Global Lead Digital Health Solutions and Medical Outcomes, Novartis on “What is driving the Digital Transformation of the Pharma Industry?”
Dr Andrew Bate, Senior Director, Analytics Team Lead, Pfizer on “AI-driven Utilisation of Real-World Evidence for R&D”
Jessica Shull, European Lead, Digital Therapeutics Alliance on “What is required for a DTx product to be successful?”
Bhushan Bonde, Head of IT – Early Solution Innovation Development, UCB on “Enabling AI Driven Drug Discovery with Cutting Edge Disruptive Platform”
Mark Campbell, Freelance regulatory expert, former NICE on “International Insight into Standards for Seamless Adoption of Prescription Digital Therapeutics”
Vladimir Anisimov, Principal Data Scientist, Amgen on “Innovative AI technologies for Predicting Patient Enrolment and Optimal Forecasting of Clinical Trials Operation”
Highlights of the event:
Novartis discusses the digital transformation approach utilising artificial intelligence, virtual reality and analyses the forces driving the convergence of PharmaTec
Pfizer explores AI-enabled real-world evidence platforms for structured data collection and analysis
Insight into the potential of Digital Therapeutics to enhance patient centricity in pharma
International insight from former NICE about the regulatory standards surrounding emerging technologies, with special focus on overcoming challenges of implementation
View the full agenda and speaker line-up online at www.disruptivetech-pharma.com/PRcom
Disruptive Technologies in Pharma
20th 21st January 2020
London, UK
www.disruptivetech-pharma.com/PRcom
Let’s block ads! (Why?)
SINGAPORE - Media OutReach Newswire - 29 April 2024 - XT, the world's first socially…
LONDON--(BUSINESS WIRE)--#BonteFriedheim--NextEnergy Capital (“NEC”), a leading global renewables manager specialised on the solar+ infrastructure sector,…
H2SITE’s AMMONIA to H2POWER technology for ammonia cracking on-board has received Approval in Principle (AiP)…
Daiichi Sankyo and AstraZeneca’s ENHERTU also demonstrated a clinically meaningful progression-free survival improvement in patients…
Q1 2024 Group sales at $7.4 billion, -20% (-18% at CER) versus prior year Q1…
Hongkong Land sees success in its unique and fully owned tenant-based, community initiative that promotes…